[Federal Register Volume 84, Number 175 (Tuesday, September 10, 2019)]
[Notices]
[Pages 47557-47558]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-19534]
-----------------------------------------------------------------------
NUCLEAR REGULATORY COMMISSION
[Docket No. 50-608; NRC-2019-0173]
SHINE Medical Technologies LLC
AGENCY: Nuclear Regulatory Commission.
ACTION: Operating license application; receipt and availability.
-----------------------------------------------------------------------
SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) staff
acknowledges receipt of an application submitted by SHINE Medical
Technologies, LLC (SHINE), dated July 17, 2019, filed
[[Page 47558]]
pursuant to the Atomic Energy Act of 1954, as amended, and the NRC's
regulations, for an operating license for the SHINE Medical Isotope
Production Facility.
DATES: This action takes effect on September 10, 2019.
ADDRESSES: Please refer to Docket ID NRC-2019-0173 when contacting the
NRC about the availability of information for this action. You may
obtain publicly-available information related to this action by any of
the following methods:
Federal Rulemaking Website: Go to https://www.regulations.gov/ and search for Docket ID NRC-2019-0173. Address
questions about NRC docket IDs in Regulations.gov to Jennifer Borges;
telephone: 301-287-9127; email: [email protected]. For technical
questions, contact the individual listed in the FOR FURTHER INFORMATION
CONTACT section of this document.
NRC's Agencywide Documents Access and Management System
(ADAMS): You may obtain publicly-available documents online in the
ADAMS Public Documents collection at https://www.nrc.gov/reading-rm/adams.html. To begin the search, select ``Begin Web-based ADAMS
Search.'' For problems with ADAMS, please contact the NRC's Public
Document Room (PDR) reference staff at 1-800-397-4209, 301-415-4737, or
by email to [email protected]. The ADAMS accession number for each
document referenced (if it is available in ADAMS) is provided the first
time that it is mentioned in this document.
NRC's PDR: You may examine and purchase copies of public
documents at the NRC's PDR, Room O1-F21, One White Flint North, 11555
Rockville Pike, Rockville, Maryland 20852.
FOR FURTHER INFORMATION CONTACT: Steven T. Lynch, Office of Nuclear
Reactor Regulation, U.S. Nuclear Regulatory Commission, Washington, DC
20555-0001, telephone: 301-415-1524; email: [email protected].
SUPPLEMENTARY INFORMATION: By letter dated July 17, 2019 (ADAMS
Accession No. ML19211C044), SHINE filed with the NRC, pursuant to
Section 103 of the Atomic Energy Act and part 50, ``Domestic Licensing
of Production and Utilization Facilities,'' of title 10 of the Code of
Federal Regulations (10 CFR), an application for an operating license
for the SHINE Medical Isotope Production Facility to be located in
Janesville, Wisconsin (ADAMS Package Accession No. ML19211C143).
SHINE has proposed to construct and operate a facility in
Janesville, Wisconsin for the production of molybdenum-99 (Mo-99)
through the irradiation and processing of a uranyl sulfate solution. As
described in the operating license application, the proposed facility
would comprise an irradiation facility and radioisotope production
facility. The irradiation facility would consist of eight subcritical
operating assemblies (or irradiation units), which would each be
licensed as a utilization facility, as defined in 10 CFR 50.2,
``Definitions,'' and supporting structures, systems, and components
(SSCs) for the irradiation of low enriched uranium. The radioisotope
production facility would consist of hot cell structures, licensed
collectively as a production facility, as defined in 10 CFR 50.2, and
associated SSCs for the processing of irradiated material and
extraction and purification of Mo-99. The irradiation facility and
radioisotope production facility are collectively referred to as the
SHINE Medical Isotope Production Facility. Issuance of the operating
license would authorize the applicant to operate the SHINE Medical
Isotope Production Facility for a 30-year period.
By letters dated March 26 and May 31, 2013 (ADAMS Accession Nos.
ML13088A192 and ML13172A361, respectively), SHINE (at the time known as
SHINE Medical Technologies, Inc.) submitted a two-part construction
permit application, as updated in 2015, for its eight utilization
facilities and one production facility (ADAMS Package Accession No.
ML15258A431). The NRC issued Construction Permit No. CPMIF-001 to SHINE
on February 29, 2016 (ADAMS Package Accession No. ML16041A473).
The acceptability of the tendered application for docketing and
other matters, including an opportunity to request a hearing, will be
the subject of subsequent Federal Register notices.
Dated at Rockville, Maryland, this 5th day of September, 2019.
For the Nuclear Regulatory Commission.
Steven T. Lynch,
Project Manager, Research and Test Reactors Licensing Branch, Division
of Licensing Projects, Office of Nuclear Reactor Regulation.
[FR Doc. 2019-19534 Filed 9-9-19; 8:45 am]
BILLING CODE 7590-01-P